Go Search

FDA Approves Once-Monthly
ABILIFY MAINTENATM (aripiprazole) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia.  To read the full press release, click here.

Please see FULL PRESCRIBING INFORMATION including Boxed WARNING for ABILIFY MAINTENA.

There are three Otsuka pharmaceutical industry companies in the U.S.:

Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America.
 To learn more, click here.

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis.
To learn more, click here.

Otsuka Maryland Medicinal Laboratories, Inc. (OMML) is a basic research center investigating pharmacological compounds.
 To learn more, click here.

 

 

 

 

 

OAPI, OPDC and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989.
OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd.